You are here: Industry Insights > sarcoma

News List

STA To Market Sarcoma Drug In Australia, New Zealand And SE Asia Following License Deal En-CPhI.CN
October 15, 2019
Independent pharmaceutical company Specialised Therapeutics Asia (STA) has signed a new license deal, enabling it to provide a global advanced sarcoma therapy to patients in Australia ...
Epizyme Submits New Drug Application to the U.S. FDA for Tazemetostat for the Treatment of Patients with Epithelioid Sarcoma drugs
June 13, 2019
Epizyme Submits New Drug Application to the U.S. FDA for Tazemetostat for the Treatment of Patients with Epithelioid Sarcoma.
Lilly to Establish an Access Program for Patients as it Prepares to Withdraw Lartruvo from the Global Market drugs
May 09, 2019
Lilly to Establish an Access Program for Patients as it Prepares to Withdraw Lartruvo from the Global Market.
TK216-vincristine combination for Ewing sarcoma identified europeanpharmaceuticalreview
May 06, 2019
TK216-vincristine combination appears to halt the ability of Ewing sarcoma to grow and progress…
Lilly to withdraw cancer drug Lartruvo from global market pharmaceutical-technology
April 28, 2019
Eli Lilly has announced an access programme for patients that wish to continue using its cancer drug Lartruvo (olaratumab) as the company prepares to withdraw the medication from markets worldwide.
New approach identifies existing leukaemia drugs that show promise for Ewing sarcoma treatment europeanpharmaceuticalreview
February 01, 2018
Scientists in the United States have discovered that two existing FDA-approved drugs, clofarabine (Clolar™) and cladribine (Leustatin™), have a powerful inhibitory impact on Ewing sarcoma cells in the lab.
European policy response to rare cancers: the case of sarcoma lilly
February 10, 2017
As an oncologist working in the area of sarcoma, I can attest to the significant disparities in the care available to sarcoma patients across Europe.